<DOC>
	<DOC>NCT02060162</DOC>
	<brief_summary>This study aims to establish a cohort of patients starting antiretroviral therapy (ART) with chronic hepatitis B virus (HBV) infection and study the effect of chronic HBV on HIV- and liver-related outcomes according to ART regimen and site.</brief_summary>
	<brief_title>Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa</brief_title>
	<detailed_description>The study will take place during routinely scheduled ART visits as per Ministry of Health guidelines. Routinely collected programmatic data will be used to assess general HIV outcomes (CD4 response, loss to follow-up, death) as well as collecting study specific data (hepatitis testing, questionnaire regarding risk factors for hepatitis/liver disease, and non-invasive liver scan) to address other aims. The study will be implemented at two sites in Southern Africa with a total enrollment across all sites of 1,900 participants. The Zambia site will only enroll 900.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>HIVinfected Male or female aged ≥18 years ART naïve ART eligible as defined by Zambian or WHO treatment guidelines Initiating an ART regimen including at least 3 drugs at one of the study sites. Willing to provide signed informed consent and be followed at the clinical site. Patients who are not planning to remain in the catchment area from which they were recruited for the duration of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>antiretroviral therapy</keyword>
	<keyword>Hepatitis C virus</keyword>
</DOC>